The control of TGFβ signaling depends on many not well understood regulators. Results TGFβ transcriptionally induces SIK1, which cooperates with the ubiquitin ligase Smurf2 to negatively regulate the signaling output.
INTRODUCTION
TGFβ signaling initiates when the extracellular dimeric TGFβ ligand associates with serine/threonine kinase receptors type II (TβRII) and type I (TβRI), also known as activin receptor-like kinase 5 (ALK5) (1) . TβRII transphosphorylates TβRI which in turn phosphorylates receptor-regulated Smads (RSmads, Smad2 and Smad3). R-Smad phosphorylation is necessary for their association with Smad4, accumulation in the nucleus and cooperation with transcriptional complexes to regulate gene expression (2) . TGFβ signaling is regulated by various mechanisms that operate outside the cell, at the cell membrane, in the cytoplasm or in the nucleus (3) . Intracellular regulation of the TGFβ signaling network relies to a large extent on the time point of signal transduction and on the cell compartment where various post-translational modifications of signaling proteins occur (4) . In this manner, the multifaceted actions of TGFβ are regulated during embryonic development, adult organ homeostasis and disease.
Among the negative regulators of TGFβ signaling are the inhibitory Smad7 and the E3 ubiquitin ligase Smurf2, both operating within a negative feedback mechanism and control the strength and duration of signal transduction (3, 4) . The Smad7 and Smurf2 genes are immediate-early TGFβ-inducible genes (5, 6) . Smad7 binds directly to ALK5 leading to competitive inhibition of Smad2 and Smad3 phosphorylation by the receptor (5, 7) . Smad7 also binds directly to Smurf2, and its homolog Smurf1, thus leading to ALK5 ubiquitination and downregulation (8, 9) . In addition, Smurf1 and Smurf2 ubiquitinate and regulate the stability of Smad proteins (10) , the mitotic checkpoint protein Mad2 that controls proper spindle assembly during cell division (11) , and also of the serine/threonine kinase MEKK2 that is required for the differentiation of bone cells (12) . Furthermore, Smurf1 and Smurf2 ubiquitinate the small GTPases RhoA and Rap1B, the actin-binding protein talin and the planar cell polarity protein Prickle, thus regulating epithelial and neuronal cell polarity, contractility of the cytoskeleton and amoeboid cell migration (13) (14) (15) (16) (17) . Such molecular functions may explain the role of Smurf1 and Smurf2 in the process of breast cancer cell invasiveness and metastasis (18, 19) .
We have previously identified a new gene target of TGFβ signaling, the salt-inducible kinase 1 (SIK1, hereby abbreviated as SIK), which encodes a serine/threonine kinase of the AMP-activated protein kinase (AMPK) family (20) . SIK has a modular structure with an Nterminal kinase domain and a middle ubiquitinassociated (UBA) domain, which is followed by a long C-terminal sequence (21) . SIK expression is induced during cardiogenesis and skeletal muscle differentiation (22) . SIK function is required for cardiomyocyte differentiation where it affects the expression of the cell cycle inhibitor p57 (23) , and for skeletal myogenesis, where SIK phosphorylates class II histone deacetylases (24) . SIK is also induced in adrenal glands, leading to steroidogenesis (25) , and regulation of sodium transport (26) . Another important pathway under the control of SIK activity is the regulation of the cAMPresponsive element binding protein (CREB) (27) . SIK directly phosphorylates and inactivates the transducer of regulated CREB activity (TORC), a critical transcriptional co-activator of CREB, and in this manner, SIK represses CREB function. The same mechanism, when catalyzed by the SIK isoform SIK2 that phosphorylates TORC2, leads to recruitment of the COP1 signalosome regulator that mediates TORC2 ubiquitination and degradation (28) . This specific mechanism appears to be defective in diabetes, resulting in TORC2 stabilization and enhancement of the gluconeogenic gene expression program. We have demonstrated that SIK also inhibits TGFβ signaling by inducing TβRI/ALK5 receptor downregulation (29) . Regulation of TGFβ signaling by SIK is compatible with independent reports on the C. elegans ortholog of SIK, KIN-29, which regulates chemosensory neuronal signaling and body size, processes dependent on TGFβ/Smad signaling (30, 31) .
In this study we have explored the mechanisms by which TGFβ regulates SIK expression and achieves ALK5 downregulation. Our findings clarify how the SIK gene is regulated by Smads, and place SIK in close association and functional interaction with the ubiquitin ligase Smurf2. Lönn et al. SIK1 and Smurf2 regulate TGF signaling 3 derived clone MCF10CA1h (MIII) and the metastatic clone MCF10CA1a.cl1 (MIV), were maintained in DMEM/F12 supplemented with 5% fetal bovine serum, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 100 U/ml penicillin, and 100 µg/ml streptomycin, and were kindly provided by F.R. Miller (Fred Hutchinson Cancer Center, Seattle, USA) (32) . The human metastatic breast cancer cell line MDA-MB-231 were maintained in DMEM supplemented with 10% bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. The mouse mammary epithelial cells NMuMG-Fucci that express two fluorescently labeled cell cycle markers (Cdt1, fused to the red fluorescent protein mKO2, and geminin, fused to the green fluorescent protein mAG) (33) , were cultured in DMEM supplemented with 10% fetal bovine serum, 10 µg/ml insulin, 100 U/ml penicillin, and 100 µg/ml streptomycin, and were kindly provided by S. Johansson (Uppsala University, Sweden). All cell lines were grown in a humidified incubator at 37°C and 5% CO2.
Adenoviruses expressing human SIK epitope-tagged with Flag at its N-terminus and control virus expression Bacterial lacZ protein were previously described by us and were amplified, titrated and propagated as described before (29) .
Recombinant human TGFβ1 was purchased from Biosource International Inc. (Camarillo, USA) or PeproTech EC Ltd. (London, UK). The TGFβ type I receptor inhibitor SB505124 was purchased from Calbiochem/MERCK (Darmstadt, Germany).
Anti-SIK antibody was made in-house and was described (29) ; anti-Flag (M5) antibody was from Sigma-Aldrich (Täby, Sweden); anti-GFP (A11122) and anti-GAPDH (AM4300, Ambion) from Invitrogen, Corp. (Carlsbad, USA); antiSmurf2 (2078-1), anti-Smad2 (1736-1), antiSmad3 (1735-1) from Epitomics, Inc. (Burlingame, CA); anti-Smad4 (H-552) and anti-TβRI/ALK5 (V-22) from Santa Cruz Biotechnology, Inc. (Santa Cruz, USA); antiSmad7 (IMG-531) from Imgenex (San Diego, USA); anti-E-cadherin from BD Transduction Laboratories (Stockholm, Sweden); anti-HA (Y-11) and mouse monoclonal anti-myc (9E10) were made in-house or purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); secondary antibodies coupled to horseradish peroxidase were from GE Healthcare (Uppsala, Sweden); secondary antibodies coupled to fluorescein isothiocyanate, tetramethylrhodamine isothiocyanate from DAKO (Glostrup, Denmark), Alexa fluor-546 from Molecular Probes/Invitrogen, Corp. (Carlsbad, CA), and AMCA7-(7-amino-4-methylcoumarin-3-acetic acid) from Jackson Immunoresearch (West Grove, PA).
Expression vectors pcDNA3-Flag-hSIK, pCS2-6myc-hSIK, pEGFP-hSIK and the SIK ATP-binding site mutant K56R were described before (29) . Vectors pcDNA3-ALK5(CA)-HA (constitutively active T204D mutant receptor with C-terminal hemagglutinin tag), pRK1-mycSmurf2 and its catalytically inactive point mutant pRK1-myc-Smurf2(CG), pcDNA3-FlagSmad3, pcDNA3-Flag-Smad4 and pcDNA3-Flag-Smad7 were described (34) . All DNA constructs were sequence verified.
Promoter cloning and luciferase-reporter constructs -The human SIK promoter-enhancer sequences were amplified from genomic DNA isolated from human HaCaT keratinocytes using primers mapping upstream and downstream of the transcriptional start site (TSS) and upstream and downstream of the investigated putative enhancer element of the human gene. For the amplification of the promoter fragment the primers used were: forward, 5´-GAGCTCATCCTCGTTTCTCCG-3´ and reverse, 5´-GAGCTCGGGTGCCTACTGCT-3´. For the amplification of the enhancer fragment the primers used were: forward, 5´-GGATCCCATGAGGAGAGCAGGC-3´ and reverse 5´-GTCGACGAGGCTGCCTGGAGAC-3´. The amplified sequences were cloned into vector pGL4.12 (Promega Corp., Madison, WI) in two steps: a) the PCR-amplified genomic DNA fragments were blunt-end ligated into the pGL4.12 vector after cutting with EcoRV. b) The subcloned promoter and enhancer fragments were removed from the first recombinant plasmids with SacI (promoter) or SalI/BamHI (enhancer) and religated back to pGL4.12, producing pGL4.12-hSIKP (carrying the human SIK promoter only), pGL4.12-hSIKPE (carrying the SIK promoter and enhancer, the latter cloned downstream of the luciferase cDNA sequence, aiming at mimicking the endogenous SIK gene organization (Fig. 3E) . The cloned promoter fragment corresponds to 1,214 bp spanning from -1,151 to + 63 bp relative to the TSS of the SIK gene.
The cloned enhancer fragment corresponds to 451 bp spanning from +14,423 to +14,874 bp relative to the TSS, sequences located in the 3´ intergenic region downstream from the SIK gene (Fig. 3E) Measurements of mRNA expression were performed as described earlier (29 Chromatin immunoprecipitation (ChIP) -HaCaT cells were cultured in 10-cm plates to 80% confluence and one plate was used per immunoprecipitation. Cells were fixed with 1% formaldehyde for 10 min at room temperature with swirling. Excess aldehyde was quenched with glycine which was added to a final concentration of 0.125 M, and the incubation was continued for an additional 5 min. Cells were washed twice with ice-cold phosphatebuffered saline, harvested, and their pellets were resuspended in 1 ml of sodium dodecyl sulfate (SDS) lysis buffer (50 mM Tris-HCl [pH 8.1], 1% SDS, 10 mM EDTA, protease inhibitors (Complete EDTA-free protease inhibitors from Roche Diagnostics, Rotkreuz, Switzerland)). Samples were sonicated 3 times for 30 sec each time (output H) at intervals of 30 sec with a Diagenode Bioruptor sonicator.
Samples were then centrifuged at 14,000 rpm at 8 °C for 10 min. After removal of a control aliquot (whole-cell extract), supernatants were diluted 10-fold in ChIP dilution buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100). Samples were incubated at 4 °C overnight in 2-methacryloyloxyethyl phosphorylcholine polymer-treated 15-ml polypropylene tubes (Assist, Japan) with anti-mouse IgG-Dynabeads that had been pre-incubated with 5 μg of antibodies in phosphate buffered saline/0.5% bovine serum albumin. The antibodies used were: mouse monoclonal anti-Smad2/Smad3 antibody (BD Transduction Labs, Stockholm), mouse monoclonal anti-Smad4 antibody (B8, Santa Cruz Biotechnology, Inc. CA); or control, pre-immune mouse immunoglobulin. The immunoprecipitated beads were then moved to 1.7-ml siliconized tubes (Corning, Corning, NY) and washed five times with ChIP wash buffer (50 mM HEPES-KOH pH 7.0, 0.5 M LiCl, 1 mM EDTA, 0.7% deoxycholate, 1% Igepal CA630) and once with TE buffer (pH 8.0). Immunoprecipitated samples were eluted and reverse cross-linked by incubation overnight at 65 °C in elution buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS). Genomic DNA was then extracted with a PCR purification kit (Qiagen NORDIC, Sollentuna).
The immunoprecipitated DNA was analyzed by qPCR assay using specific primers for the human PAI-1 promoter region: forward, 5´-GCAGGACATCCGGGAGAGA-3´and reverse, 5´-CCAATAGCCTTGGCCTGAGA-3´; for the human Smad7 promoter region: forward, 5'-TGGGTTTCGCGGTGGCCATC-3' and reverse 5'-CGCTCTCCTCCCCTTGCCCT-3'; for the human SIK enhancer region: forward, 5´-CTGAGGTTGGCTGGGCATAAGTGTG-3´ and reverse, 5´-TCAGACAGCCTCAAGCCACTAAGCC-3´; and for the human β-globin (HBB) control region:
forward, 5´-AACGTGATCGCCTTTCTC-3´and reverse, 5´-GAAGCAGAACTCTGCACTTC-3´. The qPCR protocol was: 95 o C for 5 min, followed by 39 cycles of 95 o C for 15 sec, 60 o C for 1 min (or 65 o C for 1 min for the SIK sequences) and 95 o C for 15 sec. Primer design and qPCR conditions were according to the recently published ChIP analysis of Smad-binding at a genome-wide level (35) .
Immunoblotting and immunoprecipitation assays -SDS-PAGE, immunoblot and coimmunoprecipitation analysis was as described (20, 34) . Protein G Sepharose was purchased from GE Healthcare (Uppsala, Sweden) and Dynabeads protein A from Invitrogen, Corp. (Carlsbad, CA). For the endogenous coimmunoprecipitation experiment of Smad7, Smurf2 and ALK5 after anti-SIK immunoprecipitation, anti-Flag (M5) IgG was used as negative control (see Fig. 4C ).
Immunofluorescence and confocal microscopy -Approximately 70% confluent transfected Mv1Lu monolayers were analyzed by immunofluorescence 24 h post-transfection, as described (29) . Nuclei were counterstained with 4´,6´-diamidino-2-phenylindole (DAPI) or propidium iodide. A Zeiss Axiovert 200 M confocal microscope equipped with LSM 510 laser was used with the Zeiss 63×/0.75 objective lens and photographing at ambient temperature in the presence of immersion oil. For the endogenous immunofluorescence experiments, MDA-MB-231 cells were cultured on standard 8-well glass plates prior to fixation and photomicrographs were obtained by a Zeiss Axioplan 2 microscope with a Hammamatsu C4742-95 digital camera, using the Zeiss Planneofluar 100×/01.4 Iris objective lens. For fluorescence microscopy of live NMuMG-Fucci cells growing on a culture dish, a Zeiss Axiovert 40 CFL with an AxioCam MRc digital camera was used, using the Zeiss Plan-neofluar 10×/0.3 objective lens. Primary images were acquired with the camera's Volocity (MDA-MB-231 assays), QED Camera Plug-in v.1.1.6 (QED Imaging Inc.) (Mv1Lu assays) and AxioVision v4.8.2.0 (NMuMG-Fucci) software. Image memory content was reduced and brightnesscontrast was adjusted using Adobe Photoshop CS3 Extended.
Live cell cycle analysis assay -NMuMGFucci cells were transiently transfected with siRNAs twice, followed by a transient adenoviral infection with control Ad-LacZ or Ad-SIK viruses as described above. Forty eight hours after the first siRNA transfection and 24 h after the adenoviral infection and second siRNA transfection, cells were stimulated with vehicle or TGFβ1 for 56 h prior to fluorescence microscopy and image acquisition as explained above. The red and green fluorescent cells were counted using the ImageJ software (http://rsbweb.nih.gov/ij/) and are expressed as percent of red or green cells relative to the total number of cells counted. For each independent condition, two photomicrographs were captured by the microscope's camera, and two separate fields of 500 cells were counted. The numbers of cells were averaged among the two fields and the two independent photomicrographs to calculate the percentage of red or green cells.
RESULTS
Comparative analysis of SIK and Smad7 mRNA induction by TGFβ -We have previously shown that SIK downregulates the TβRI/ALK5 in cooperation with Smad7 (29) . Interestingly, both SIK and Smad7 are upregulated relatively early after TGFβ stimulation and their mRNAs showed roughly 7-fold peak induction after 1 h of TGFβ stimulation in HaCaT cells (Fig. 1A,   B ). The transcriptional induction of SIK mRNA has previously been seen in mouse mammary epithelial NMuMG cells (36) , human breast cancer MDA-MB-468 cells (20) , and in independent studies of transcriptomic responses to TGFβ (37, 38) . We confirmed such previous reports beyond the HaCaT cell system, by measuring induction of SIK and Smad7 mRNAs by TGFβ after 1 h stimulation of human breast epithelial cells MCF10A (MI), their Rastransformed derivatives (MII) and tumorigenic clones derived from the latter (MIII and MIV) and in the human metastatic breast cancer cell line MDA-MB-231 (Suppl. Fig. 1A, B) .
The increase on SIK and Smad7 mRNA levels depended on RNA polymerase II activity as actinomycin D (ActD) reduced the levels of each mRNA to background and TGFβ was unable to exert any effect in the presence of ActD (Fig. 1A, B) . As control, ActD was shown to minimally or not at all affect expression of the 5S rRNA that is transcribed by RNA polymerase III (Suppl. Fig. 1C ). TGFβ signaling did not appreciably alter 5S rRNA levels as expected. These data confirm that TGFβ does not act by stabilizing the mRNA of SIK or Smad7.
Next, we compared the regulation of SIK and Smad7 mRNA levels over longer times of TGFβ stimulation (0-24 h) and examined whether both genes are direct targets of TGFβ/Smad signaling ( Fig. 1C-F) . Both SIK and Smad7 mRNAs rapidly reached peak levels after 1-2 h stimulation and their expression remained elevated above basal levels throughout the 24 h period (Fig. 1C, D) .
Treating HaCaT cells with cycloheximide (CHX) prior to stimulation in order to block de novo protein synthesis did not inhibit SIK and Smad7 mRNA induction by TGFβ (Fig. 1E, F) . This indicates that both SIK and Smad7 are direct target genes of TGFβ signaling. Interestingly however, the long-term pattern of mRNA expression changed with the addition of CHX. Both SIK and Smad7 mRNAs accumulated slower, reaching their peak levels at 4 h (Fig. 1E, F) . Also notable is that when de novo protein synthesis was blocked, neither of the two genes could uphold its plateau levels, as the peak of expression was followed by a slow but steady decline towards basal levels during the 24 h time course. In summary, the rapid mRNA accumulation of SIK and Smad7 by TGFβ is independent of de novo protein synthesis (Fig. 1 ). This strongly suggests that both genes are direct targets of the TGFβ signaling pathway and their regulation can be verified in all mouse and human cell models examined so far.
Smad-dependent transcriptional regulation of SIK in response to TGFβ -The direct effect of TGFβ on SIK gene expression (Fig. 1) suggested that Smad signaling might be responsible for this regulation. Knock-down of each Smad protein of the TGFβ pathway in HaCaT cells showed that Smad2, Smad3 as well as Smad4 contribute to the upregulation of SIK and Smad7 mRNAs ( Fig. 2A, B) . We confirmed the efficiency of Smad knock-down by measuring their respective mRNA level ( Fig.  2C -E) and corresponding protein level (Fig. 2F-G) . It is worth noting that the Smad3 siRNA pool used was less efficient compared to the Smad2 and Smad4 siRNA pools. Despite this, the knock-down of Smad3 had a strong impact on SIK and Smad7 gene expression ( Fig. 2A,  B) . Thus, quantitatively Smad3 and Smad4 have a larger impact on the induction of SIK and Smad7 mRNA than Smad2. The contribution of each Smad to the induction of SIK and Smad7 mRNA seems to be similar between these two genes, suggesting that the same organization of Smad complexes might regulate their enhancers/promoters.
We then verified the presence of Smad complexes on a SIK enhancer region residing downstream of the 3´ end of the SIK gene (Fig.  3) . This region was previously identified in a genome-wide screen for TGFβ-induced Smad2/3 binding using ChIP-chip analysis in HaCaT cells (35) . Immunoprecipitation of Smad2/Smad3 revealed recruitment of these Smads to the SIK enhancer under control conditions and this recruitment was enhanced ~2.7-fold after TGFβ stimulation (Fig. 3A) . This recruitment was specific to the SIK enhancer as shown by lack of Smad2/3 recruitment to the control HBB gene sequence (Fig. 3B ). Smad2/3 binding to the SIK enhancer exhibited similar pattern to those of the well characterized promoters of the PAI-1 and Smad7 genes (Fig. 3C, D) . A similar experiment with a Smad4-specific antibody confirmed the above result (Suppl. Fig. 2) . A clear TGFβ-dependent enrichment of SIK enhancer chromatin was measured in the Smad4 immunocomplexes (Suppl. Fig. 2A ), similar to the PAI-1 promoter enrichment (Suppl. Fig. 2C ) and unlike the negative control HBB sequence (Suppl. Fig. 2B) .
To confirm the endogenous ChIP data on the role of the SIK enhancer, we cloned the human SIK promoter and enhancer into a luciferase reporter construct (Fig. 3E) , and performed promoter activation experiments in transfected HEK-293T cells. As predicted from the Smad-binding ChIP assays, the upstream promoter could be activated weakly by TGFβ and/or co-transfection of Smad3 and Smad4 (Fig. 3F, G) . However, a luciferase construct that carried both the SIK promoter and the enhancer cloned downstream from the luciferase cDNA, showed higher basal activity (Fig. 3F ) and responded better to TGFβ and/or Smad3/Smad4 co-transfection (Fig. 3F, G) .
In conclusion, this analysis demonstrates that TGFβ signaling sends the Smad complex to the 3´ intergenic enhancer of the SIK gene. This mechanism of gene regulation can only be partially recapitulated in vitro after cloning the enhancer element downstream of the basic promoter unit of this gene, which implies that additional regulatory sequences mediating TGFβ responses may exist on the SIK gene.
Smurf2 forms complexes with SIK and Smad7 -We have previously investigated the cooperation between SIK and Smad7 in downregulating the TβRI/ALK5 receptor (29) , however, the mechanism whereby SIK works together with Smad7 has not been clear. A possible link could be the E3 ubiquitin ligase Smurf2, which is known to be induced upon TGFβ stimulation, interacts with ALK5 and Smad7 and targets ALK5 receptors for ubiquitination (8, 9) . We verified that Smurf2 mRNA is rapidly but weakly upregulated by TGFβ signaling in HaCaT cells, even in the presence of CHX (Fig. 4A) . Furthermore, the weak but reproducible induction of Smurf2 mRNA by TGFβ could also be verified in three (MI, MII, MIV) out of the five breast cancer cell lines tested (Suppl. Fig. 3A) .
Interaction between Smad7 and SIK has been shown previously (29) . Here we further investigated a possible complex formation between Smad7, Smurf2 and SIK. First, we immunoprecipitated Flag-Smad7 and confirmed that it could bind both 6Myc-SIK and catalytically inactive Myc-Smurf2 (C716G), which was used to avoid strong degradation of the proteins in the complex (Fig. 4B) Fig. 3B ). Using our home-made anti-SIK antibody and HaCaT cell extracts we immunoprecipitated endogenous SIK from cells stimulated with vehicle or TGFβ (Fig. 4C ). In the absence of TGFβ stimulation we observed a complex with endogenous Smad7 and ALK5. After TGFβ stimulation, the complex between SIK, Smad7 and ALK5 was again visible and it now had incorporated also Smurf2. This experiment also demonstrated the induction of endogenous protein levels of SIK, Smad7 and Smurf2 by TGFβ and the concomitant downregulation of the ALK5 receptor (Fig. 4C) .
We then examined the role of the kinase activity of SIK on formation of protein complexes between Smad7, Smurf2 and SIK (Fig. 4D ). Smad7 and SIK interacted irrespectively of the kinase activity of SIK (Fig.  4D, lanes 4 and 7) . The protein complex between SIK and Smad7 was weakly enhanced by the presence of wild-type Smurf2 (Fig. 4D,  lane 5) , however, addition of catalytically inactive Smurf2(C716G) dramatically enhanced the complex between the three proteins ( Fig 4D,  lane 6) , at equal expression levels of wild type and mutant Smurf2 (Fig. 4D) . Surprisingly, when the same co-immunoprecipitation experiment was repeated with the SIK(K56R) mutant instead of wild-type kinase, the ability of Smurf2(C716G) to promote an enhanced SIK/Smad7/Smurf2 complex was reduced (Fig.  4D, lanes 8 and 9) . This suggests that the catalytic activity of SIK has an impact on formation of the complex between these three proteins. Lack of strongly enhanced protein complex accumulation by the wild-type Smurf2 is most likely due to the rapid dissociation or degradation caused by the recruitment of active Smurf2 into this complex, making it difficult to visualize the dynamics of this protein complex.
Overall, these biochemical experiments suggested that SIK, Smad7 and Smurf2 are induced by TGF signaling and can engage with each other in mutual complexes.
SIK cooperates with Smurf2 and Smad7 to downregulate the TβRI/ALK5 receptor -The interaction data suggested that the two enzymes, SIK and Smurf2, cooperate or depend on each other during TGFβ receptor downregulation. We tested this possibility by co-expressing wild-type SIK and Smurf2 (Fig. 5A ). Increasing levels of SIK led to downregulation of the constitutively active (CA) ALK5 receptor and Smurf2 combined with wild-type SIK had the same effect. Combining Smad7 with SIK had a similar effect on receptor downregulation, but when we co-expressed SIK, Smurf2 and Smad7 we then observed essentially complete loss of the receptor (Fig. 5A) . In a similar experiment where the level of Smurf2 was increased, we observed the same cooperation between SIK and Smurf2 on ALK5 receptor downregulation (Suppl. Fig. 4A ). Smurf2 also led to a significant downregulation of SIK and the presence of Smad7 enhanced this effect.
We examined the role of the kinase activity of SIK for TβRI/ALK5 receptor downregulation and its cooperation with Smurf2 (Fig. 5B) . Catalytically inactive SIK(K56R), blocked the effects of Smurf2 on receptor downregulation (Fig. 5B) . This implies that Smurf2 downregulates the TGFβ receptor more effectively when it cooperates with a catalytically active SIK.
Smurf2 resides in the nucleus and moves, together with Smad7, to the cytoplasm in response to TGF in order to reach the ALK5 receptor (9) . SIK shuttles between the cytoplasm and the nucleus and its localization can be regulated by steroids or by the 14-3-3 adaptor protein (25, 39) . Using immunofluorescence experiments we investigated localization of SIK, Smurf2 and ALK5. In transfected, TGF-sensitive Mv1Lu cells, SIK showed both nuclear and cytoplasmic distribution, as expected, but additionally localized close to the plasma membrane in pronounced punctated clusters (Fig. 5C ). Co-localization of SIK, CA-ALK5 and Smurf2 was observed in these peripheral clusters (Fig. 5C, insets) , with no obvious colocalization in the more diffuse pattern scattered in the rest of the cell body. Thus, SIK, Smurf2 and ALK5 may be able to form complexes in cytoplasmic regions proximal to the plasma membrane. We also attempted to perform the co-localization experiments at the endogenous level. We were hampered from succeeding on this aim as all of our antibodies that gave positive and specific results with endogenous proteins are raised in rabbits and thus prohibit us from performing double or triple immunofluorescence experiments. Despite this, single antibody experiments verified TGFβ-induced expression and distribution of endogenous SIK, Smad7 and Smurf2 in the nucleus and cytoplasm of HaCaT (not shown) and MDA-MB-231 cells (Suppl. Fig. 4B ). In conclusion, the evidence so far supports the existence of protein complexes between SIK, Smad7 and Smurf2 that could initiate the process of receptor turnover.
Functional cooperation of SIK and Smurf2 in regulation of endogenous TGFβ signalingTo further investigate the effects of endogenous SIK and Smurf2 on TGFβ signaling we performed siRNA knock-downs and subsequently analyzed established cellular responses to TGFβ. The efficiency of silencing of SIK, Smurf2 or both was significant at both mRNA and protein levels (Suppl. Fig. 5 ). We first analyzed the mRNA levels of wellestablished target genes of TGFβ, such as p21, Smad7, Gadd45β, fibronectin, and PAI-1 (Fig.  6A , and Suppl. Fig. 6 ). When SIK, Smurf2 or both were silenced, all these target genes showed enhanced magnitude of response to TGFβ (Fig. 6A, Suppl. Fig. 6 ). We did not observe any gene-specific differences in terms of the effect of silencing of SIK or Smurf2 on this set of genes, which is compatible with a role of SIK and Smurf2 at the receptor level. Overall, the observed enhancement in gene responses was similar after SIK or Smurf2 silencing (Fig.  6A, Suppl. Fig. 6 ). Interestingly, during simultaneous silencing of both SIK and Smurf2, we observed similar gene responses as after single silencing (Fig. 6A, Suppl. Fig. 6 ). The latter result is compatible with the model that SIK and Smurf2 participate in the same linear pathway or possibly act as part of one and the same functional protein complex as suggested by the biochemical evidence.
One of the hallmarks of biological TGFβ responses in epithelial cells is the cell cycle arrest at the early G1 phase mediated by transcriptional induction of cell cycle inhibitors such as p21 (40) . We therefore examined the impact of SIK on TGFβ-mediated epithelial cell growth arrest using the well established model of mouse mammary epithelial NMuMG cells. We employed a stable clone of NMuMG that expresses two fluorescent proteins providing the cell with a fluorescent ubiquitination-based cell cycle indication (Fucci) (33) . In this system, the green fluorescent protein mAG fused to geminin marks cells in S/M/G2 phases while the red fluorescent protein mKO2 fused to Cdt1 marks cells in G1/G0 phases. The cells were either transiently transfected with siRNA against endogenous SIK or with an adenoviral vector expressing SIK (Fig. 6B) . TGFβ clearly induced cell cycle arrest in control cells as it shifted the percentage of cells in G1/G0 from 25% to 80% (Fig. 6C) . SIK overexpression via the adenoviral vector had minor effects on the basal level of cycling cells, but had a strong negative effect on the response to TGFβ, reducing the cell cycle arrested cells from 80% to 58%. Conversely, silencing the endogenous SIK led to again minimal basal effects, but essentially 98% of the cells in multiple cultures became arrested in G1/G0 (Fig. 6B, C) . The above data collectively demonstrate that SIK mediates a significant negative regulatory effect that appears to be specific to TGFβ, and for SIK to elicit this function, complementation with additional inhibitors of the TGFβ pathway is required.
DISCUSSION
SIK has been shown to be a negative regulator of TGFβ receptor signaling (29) . Here we provide insights into the mechanisms of (i) TGFβ-induced SIK gene expression and (ii) TGFβ type I receptor downregulation by SIK (Fig. 7) . We describe that: a) the SIK gene is a direct target of TGFβ/Smad signaling and its protein product participates in protein complexes to downregulate ALK5; b) the kinase activity of SIK and the ubiquitin ligase activity of Smurf2 affect the dynamics of protein complexes with Smad7 and both are required for optimal ALK5 downregulation; c) the regulation of receptor levels has an immediate impact on physiological signaling by TGFβ and this includes several genes and the cytostatic response.
SIK and Smad7 exhibit both direct (cycloheximide-insensitive/actinomycin Dsensitive) early transcriptional peaks and prolonged profiles of sustained expression that are indirect (cycloheximide-sensitive/ actinomycin D-sensitive) (Fig. 1) . It is possible that newly synthesized Smads are required for the expression of SIK and Smad7 over long periods of time. More likely, sustained SIK and Smad7 induction by TGFβ requires the synthesis of additional transcriptional cofactors or regulators of mRNA processing as it has been previously established for other genes responding to TGFβ signaling (40) . At this stage, we have not yet identified putative regulatory proteins whose synthesis is required for the sustained SIK or Smad7 expression.
The regulation of SIK gene expression by TGFβ was previously found to be dependent on Smad4, based on genome-wide studies in the Smad4-deficient breast cancer cell line MDA-MB-468 (20) . Here we established that all three Smads of the TGFβ pathway, Smad2, Smad3 and Smad4 contribute to the accumulation of SIK and Smad7 mRNA in response to TGFβ (Fig. 2) . This is an important finding as previous genome-wide attempts to define the contribution of each one of the TGFβ pathway Smads to target gene expression have not delivered clear conclusions due to differences in the technical platforms used or differences in the cell models used (35, (41) (42) (43) . Finally, ChIP assays at the endogenous level and cloned promoter assays in transfected cells established that at least one Smad-sensitive genomic region resides in the 3´ direction of the SIK gene (Fig. 3) . This enhancer element seems to account for a significant part of the SIK gene response to TGFβ; however, the experimental evidence suggests the existence of additional TGFβ-responding regulatory sequences on this gene.
The mechanism by which SIK acts on TβRI/ALK5 clearly involves the adaptor protein Smad7 (29) , and the E3 ubiquitin ligase Smurf2 (Figs. 4, 5 ). Since Smurf2 ubiquitination activity has been linked to the regulation of Smad protein stability and function (4), it is possible that SIK might also regulate Smad protein function and turnover in addition to the regulation of the TGFβ type I receptor.
An important event during the cooperative action of these proteins towards TβRI/ALK5 seems to be phosphorylation by SIK, as its kinase activity is critical for receptor downregulation. At this stage we do not know the substrate(s) of the SIK kinase in the TβRI-Smad7-Smurf2 complex. One possibility is that formation and function of this protein complex requires phosphorylation by SIK. Alternatively, SIK-mediated phosphorylation might promote receptor trafficking to lysosomes/proteasomes for degradation. The latter model is compatible with our unpublished evidence, which does not support a role of SIK in inducing ALK5 ubiquitination. SIK rather recognizes ubiquitinated Smad7 (or other proteins) via its UBA domain and localizes in proteasome-rich locations (29) . Future work in the direction of understanding the role of SIK-mediated phosphorylation during TGFβ receptor internalization and degradation is warranted.
Altering the levels of SIK in epithelial cells clearly showed an impact on cell cycle regulation by TGFβ (Fig. 6) . However, we failed to observe effects on the cell cycle in the absence of TGFβ signaling (Fig. 6C) suggesting that SIK may not play an important functional role in regulating the cell cycle, but rather acts as a regulator of other pathways, such as TGFβ, that feed into the control of cell division.
In summary, SIK provides molecular means for multifunctional regulation of the TGFβ receptor-Smad7 complex (Fig. 7) . More work into the mechanistic details of SIK-mediated TGFβ receptor regulation could uncover novel targets for therapeutic intervention against the TGFβ pathway. 
